Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 5, 2008, Pages 1145-1153

  van der Lugt, Jasper ^a,b   Autar, Reshma Saskia ^a,b   Ubolyam, Sasiwimol ^a   Garcia, Evian Fernandez ^b   Sankote, Jongkol ^a   Avihingson, Anchalee ^a   Chuenyam, Theshinee ^a   Cooper, David A ^a,c   Lange, Joep ^a,b,d   Phanuphak, Praphan ^a,e   Wit, Ferdinand ^b,d   Ruxrungtham, Kiat ^a,e   Burger, David ^f  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b National Antiretroviral Therapy Evaluation Center   (Netherlands)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e CHULALONGKORN UNIVERSITY   (Thailand)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Dose reduction; Efficacy; Lopinavir; Saquinavir; Viral dynamics

Indexed keywords

INSULIN; LAMIVUDINE; LOPERAMIDE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; POTASSIUM CHLORIDE; PROTEINASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATITIS B; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIA; HYPOKALEMIA; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; OPEN STUDY; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THAILAND; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRUS LOAD; VOMITING;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PROTEASE INHIBITORS;

EID: 42149113999     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn050     Document Type: Article

References (37)

1. Palella FJ, Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-60.
2. Bartlett JA, Fath MJ, Demasi R et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20: 2051-64.
3. Paredes R, Mocroft A, Kirk O et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: Results from the EuroSIDA study. Arch Intern Med 2000; 160: 1123-32.
4. Bartlett JA, Buda JJ, von Scheele B et al. Minimizing resistance consequences after virologic failure on initial combination therapy: A systematic overview. J Acquir Immune Defic Syndr 2006; 41: 323-31.
5. Howard AA, Amsten JH, Lo Y et al. A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS 2002; 16: 2175-82.
6. Palella FJ Jr, Chmiel JS, Moorman AC et al. Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients. AIDS 2002; 16: 1617-26.
7. Kaufmann GR, Khanna N, Weber R et al. Long-term virological response to multiple sequential regimens of highly active antiretroviral therapy for HIV infection. Antivir Ther 2004; 9: 263-74.
8. Sungkanuparph S, Manosuthi W, Kiertiburanakul S et al. Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis 2007; 44: 447-52.
9. Getahun A, Tansuphasawadikul S, Desakom V et al. Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection. J Med Assoc Thai 2006; 89: 1472-8.
10. Autar RS, Boffito M, Hassink E et al. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother 2005; 56: 908-13.
11. Autar RS, Ananworanich J, Apateerapong W et al. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. J Antimicrob Chemother 2004; 54: 785-90.
12. Boyd M, Mootsikapun P, Burger D et al. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients. Antivir Ther 2005; 10: 301-7.
13. Stephan C, Hentig N, Kourbeti I et al. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 2004; 18: 503-8.
14. Hammer SM, Vaida F, Bennett KK et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: A randomized trial. JAMA 2002; 288: 169-80.
15. Ribera E, Lopez RM, Diaz M et al. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2004; 48: 4256-62.
16. Staszewski S, Babacan E, Stephan C et al. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J Antimicrob Chemother 2006; 58: 1024-30.
17. Molla A, Mo H, Vasavanonda S et al. In vitro antiviral interaction of lopinavir with other protease inhibitors. Antimicrob Agents Chemother 2002; 46: 2249-53.
18. Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S et al. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. J Int Assoc Physicians AIDS Care (Chic III) 2006; 5: 152-6.
19. Sukasem C, Churdboonchart V, Chasombat S et al. Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand. Infection 2007; 35: 81-8.
20. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003; 25: 393-9.
21. Droste JA, Aarnoutse RE, Koopmans PP et al. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr 2003; 32: 287-91.
22. la Porte CJ, Wasmuth JC, Schneider K et al. Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS 2003; 17: 1700-2.
23. Zeldin RK, Petruschke RA. Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004; 53: 4-9.
24. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001; 2: 105-13.
25. Hsu A, Granneman GR, Cao G et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther 1998; 63: 453-64.
26. Boffito M, Dickinson L, Hill A et al. Steady-state pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. J Acquir Immune Defic Syndr 2004; 37 1376-84.
27. Kilby JM, Hill A, Buss N. The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: Combined analysis of pharmacokinetic data from 97 subjects. HIV Med 2002; 3: 97-104.
28. Cameron DW, Becker S, King MS et al. Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/ lamivudine nucleoside regimen. J Antimicrob Chemother 2007; 59 957-63.
29. Hellinger J, Cohen C, Morris A et al. Pilot study of saquinavir and lopinavir/ritonavir twice daily in protease, inhibitor-naive HIV-positive patients. HIV Clin Trials 2005; 6: 107-17.
30. Eron J Jr, Yeni P, Gathe J Jr et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial. Lancet 2006; 368: 476-82.
31. Pozniak AL, Gallant JE, DeJesus E et al. Tonofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dope zidovudine/ lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43: 535-40.
32. Zhou J, Paton, NI, Ditangco R et al. Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Obserivational Database. HIV Med 2007; 8 8-16.
33. Kiertiburanakul S, Khongnorasat S, Rattanasiri S et al. Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients. J Med Assoc Thai 2007; 90: 237-43.
34. Notermans DW, Jurriaans S, de Wolf F et al. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group. AIDS 1998; 12: 167-73.
35. Reijers MH, Weverling GJ, Jurriaans S et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998; 352: 185-90.
36. Boyd MA, Dixit NM, Siangphoe U et al. Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: A randomized, controlled trial (HIV-NAT 012). J Infect Dis 2006; 194: 1319-22.
37. Louie M, Hogan C, Di Mascio M et al. Determining the relative efficacy of highly active antiretroviral therapy. J Infect Dis 2003; 187: 896-900.